Adjuvant Capital
New York, USA · Series A → Series B
Their stated focus (public profile)
Adjuvant Capital is a venture capital firm focused on financing life science technologies that address high-burden public health challenges in low- and middle-income countries. The firm targets neglected and emerging infectious diseases (HIV/AIDS, tuberculosis, malaria, pandemic threats, AMR), as well as maternal and child health, reproductive and sexual health, and nutrition. The majority of investments are preferred equity in technologies with demonstrated human safety and efficacy (Phase II or later), aiming to generate 'double-bottom-line' social and financial returns.
Stages: Series A → Series B
Sectors: Healthtech, Life sciences, Vaccines, Medtech, Wellness, Femtech / women's health
On file: 15 partners on record · 19 companies on record
Website: adjuvantcapital.com
This perch was compiled from public sources — filings, the fund’s own site, public write-ups. None of it is the fund’s own words.
Is this your fund? Request a correction or removal.
Search the funds we have on file
Looking for investors? Search the funds we have on file — what they back, where they are, and whether your raise fits. Sign in and Percy matches you to the right ones.
Looking to claim your own fund? Start here →
This perch was compiled from public sources — filings, the fund’s own site, public write-ups. None of it is the fund’s own words.
Funds closest to this thesis
Ordered by how close each thesis sits to this one.
Is this your fund? Request a correction or removal.